Skip to main content
Suzhou Highfine Biotech Co., Ltd. logo

Suzhou Highfine Biotech Co., Ltd. — Investor Relations & Filings

Ticker · 301393 ISIN · CNE1000064T6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2026-05-14 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 301393

About Suzhou Highfine Biotech Co., Ltd.

https://www.highfine.com

Suzhou Highfine Biotech Co., Ltd. is a specialized manufacturer and supplier of high-quality biochemical reagents and chemical building blocks. The company focuses on the research, development, and large-scale production of peptide synthesis reagents, protected amino acids, and linkers for antibody-drug conjugates (ADCs). Its core product portfolio includes coupling reagents, Fmoc and Boc-protected amino acids, and various PEG derivatives. Highfine Biotech serves a global clientele comprising pharmaceutical corporations, biotechnology enterprises, and academic research institutions. By leveraging advanced synthesis technologies and rigorous quality control standards, the company provides essential materials for drug discovery and development. Its expertise extends to custom synthesis services, catering to specific molecular requirements for complex chemical synthesis and therapeutic research.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 91% confidence The document is an official announcement of the company’s 2025 annual equity distribution plan, providing detailed cash dividend per share, total dividend amount, record date, ex-dividend date, dividend recipients, tax treatment, and payment methods. It is not a full financial report but a specific dividend notice to shareholders. This matches the definition of “Notice of Dividend Amount” (DIV).
2026-05-14 Chinese
国联民生证券承销保荐有限公司关于苏州昊帆生物股份有限公司2025年度跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a '2025年度跟踪报告' (2025 Annual Tracking Report) issued by a securities underwriting and sponsorship company regarding a listed company. It details the sponsor's review and supervision activities over the company, including information disclosure, internal controls, fundraising supervision, governance, and compliance with commitments. It does not contain financial statements or detailed financial performance data but rather a supervisory and compliance report on the company's governance and sponsor's work. The document length is 2318 characters, relatively short and focused on sponsor oversight rather than financial results or management discussion. This type of document aligns with a regulatory or compliance report related to sponsor duties rather than an annual report, interim report, or earnings release. It is not a simple announcement or certification but a substantive sponsor tracking report. Given the filing definitions, this fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit other specific categories.
2026-05-08 Chinese
上海市广发律师事务所关于苏州昊帆生物股份有限公司2025年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, and voting results of the 2025 Annual General Meeting (AGM) of Suzhou Haofan Biological Co., Ltd. It details the meeting date, location, voting methods, attendance, and the results of various resolutions voted on during the AGM. The document does not contain the actual annual report or financial statements but focuses on the legality and validity of the AGM process and voting outcomes. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. The document length is 4321 characters, which is relatively short but contains detailed voting results and legal opinions on the meeting's validity, not just an announcement of the meeting or report publication. Therefore, the correct classification is DVA with high confidence.
2026-05-08 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 Annual General Meeting (AGM) of Suzhou Haofan Bio Co., Ltd. It includes voting results on various proposals such as the 2025 Board Work Report, the 2025 Annual Report and its summary, the 2026 director remuneration plan, profit distribution proposals, and other shareholder meeting matters. The document also confirms the legality and validity of the meeting and voting process, and includes legal opinions from lawyers who witnessed the meeting. The document length is 3126 characters, which is relatively short but contains detailed voting results and resolutions, indicating it is not merely an announcement of a report publication but the actual voting results from the AGM. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-08 Chinese
2025年度独立董事述职报告（徐小平）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025 by an independent director of Suzhou Haofan Bio Co., Ltd. It details the director's activities, attendance at board and committee meetings, communication with auditors, and oversight of company governance and compliance during the year. The content focuses on the director's duties, observations, and evaluations rather than presenting financial statements or audit results. It is a narrative report on board/management activities and governance oversight rather than a financial report or audit report. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports.
2026-04-16 Chinese
2025年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year ending December 31, 2025, issued by the board of directors of Suzhou Haofan Biotech Co., Ltd. It details the company's internal control environment, risk assessment, control activities, information and communication, supervision, and evaluation criteria for internal control defects. The report includes conclusions on the effectiveness of internal controls over financial reporting and non-financial reporting, and it is dated April 15, 2026. This type of document is a standalone audit-related report focusing on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR). It is not a full annual report (10-K), nor is it a brief announcement or a certification letter. The length and detailed content confirm it is the report itself, not just an announcement. Therefore, the correct classification is AR with high confidence. FY 2025
2026-04-16 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.